Effectiveness of n-3 fatty acids in the treatment of hypertriglyceridemia in HIV/AIDS patients: a meta-analysis

Abstract Hypertriglyceridemia is common in antiretroviral therapy-treated patients and Omega 3 fatty acids are being used as a intervention in reducing serum triglycerides (TG) in these patients. The objective of this study is to evaluate the effectiveness of the use of Omega 3 in the treatment of hypertriglyceridemia in HIV/AIDS patients on antiretroviral therapy. This study is a systematic review with meta-analysis of randomized clinical trials. Electronic databases – PubMed, Cochrane and Lilacs were researched. Fifty one articles were encountered. Nine were added to the meta-analysis. The reduction of triglycerides level was -77.55 mg (IC of -121.85 to -33.25) in Omega 3 groups. The analysis considering trials with more than 1000 mg of EPA/DHA included seven studies and the heterogeneity dropped to 0%.The reduction of combined averages was -101.56mg (IC of -145.76 to -57.37). The analysis considering trials with patients that had more than 200 mg/dL of initial triglycerides included also seven trials and the heterogeneity dropped to 0%. The reduction of combined averages was -114.15 mg (IC of -162.34 to -65.97). EPA/DHA supplementation reduces serum triglycerides levels in patients with HIV/AIDS-associated hypertriglyceridemia in stable use of antiretroviral therapy.

Download Full-text

Omega-3 Fatty Acids and Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Systematic Review and Meta-analysis

HIV Clinical Trials ◽

10.1310/hct1205-268 ◽

2011 ◽

Vol 12 (5) ◽

pp. 268-274 ◽

Cited By ~ 16

Author(s):

Julicristie M. Oliveira ◽

Patrícia H.C. Rondó

Keyword(s):

Systematic Review ◽

Fatty Acids ◽

Antiretroviral Therapy ◽

Meta Analysis ◽

Omega 3 Fatty Acids ◽

Omega 3

Download Full-text

Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Nutrients ◽

10.3390/nu11112599 ◽

2019 ◽

Vol 11 (11) ◽

pp. 2599 ◽

Cited By ~ 7

Author(s):

Akira Sekikawa ◽

Chendi Cui ◽

Daisuke Sugiyama ◽

Anthony Fabio ◽

William S. Harris ◽

...

Keyword(s):

Systematic Review ◽

Fatty Acids ◽

Randomized Clinical Trials ◽

Controlled Trial ◽

Meta Analysis ◽

High Dose ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Icosapent Ethyl ◽

Central Register

A recent randomized controlled trial (RCT), the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT), reported that high-dose marine omega-3 fatty acids (OM3) significantly reduce cardiovascular disease (CVD) outcomes, yet the mechanisms responsible for this benefit remain unknown. To test the hypothesis that high-dose OM3 is anti-atherosclerotic, we performed a systematic review and meta-analysis of RCT of high-dose OM3 on atherosclerosis. The protocol of this systematic review was registered with PROSPERO (CRD42019125566). PubMed, Embase, Cochran Central Register for Controlled Trials, and Clinicaltrials.gov databases were searched using the following criteria: adult participants, high-dose OM3 (defined as ≥3.0 g/day, or in Japan 1.8 g/day and purity ≥90%) as the intervention, changes in atherosclerosis as the outcome, and RCTs with an intervention duration of ≥6 months. A random-effects meta-analysis was used to pool estimates across studies. Among the 598 articles retrieved, six articles met our criteria. Four RCTs evaluated atherosclerosis in the coronary and two in the carotid arteries. High-dose OM3 significantly slowed the progression of atherosclerosis (standardized mean difference −1.97, 95% confidence interval −3.01, −0.94, p < 0.001). The results indicate that anti-atherosclerotic effect of high-dose OM3 is one potential mechanism in reducing CVD outcomes demonstrated in the REDUCE-IT trial.

Download Full-text